Ricky Wirawan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ricky Wirawan has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Franz Bracher
Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Munich, Germany
5 shared publications - Thomas Wein
Department of Pharmacy, Ludwig-Maximilians-Universität München, Munich, Germany
4 shared publications - Matthias Frei
Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Butenandtstr. 5–13, 81377 Munich, Germany
3 shared publications - Anna Heider
Center for Functional Protein Assemblies & Department of Bioscience, TUM School of Natural Sciences, Technical University of Munich (TUM), 85748 Garching, Germany
1 shared publication - Carina Glas
Department of Pharmacy, Center for Drug Research, Ludwig-Maximilians University, Butenandtstraße 5-13, 81377, Munich, Germany
1 shared publication - Eva Maria Huber
Technical University of Munich TUM School of Natural Sciences Department of Bioscience Center for Protein Assemblies 85748 Garching Germany
1 shared publication
Latest Publications
- Open Access
- 10 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9855
Lead Structure-Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal-Type Sirt2 Inhibitors
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic strategy for the treatment of currently incurable diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis. Guided by molecular docking and MM/GBSA validation studies, a lead structure-based hybridization strategy was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93, we present a highly potent and subtype selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and contributes to the extension of the current SAR profile. The structural modification strategy employed in this study proved to be highly promising, resulting in the identification of the most potent low-molecular-weight Sirt2 inhibitor reported to date, providing a promising target for further medicinal chemistry-driven SAR studies.
- 10 October 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (20) , 9855
Open AccessLead Structure-Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal-Type Sirt2 Inhibitors
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic strategy for the treatment of currently incurable diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, and multiple sclerosis. Guided by molecular docking and MM/GBSA validation studies, a lead structure-based hybridization strategy was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93, we present a highly potent and subtype selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and contributes to the extension of the current SAR profile. The structural modification strategy employed in this study proved to be highly promising, resulting in the identification of the most potent low-molecular-weight Sirt2 inhibitor reported to date, providing a promising target for further medicinal chemistry-driven SAR studies.
- Open Access
Balsalazide-Derived Heterotriaryls as Sirtuin 5 Inhibitors: A Case Study of a Reversible Covalent Inhibition Strategy
Sirtuin 5 is an NAD+-dependent lysine deacylase that is involved in various biological processes and has emerged as a promising target for pharmaceutical therapies. The development of highly potent and subtype-selective sirtuin 5 inhibitors for their application as chemical tools and drug candidates still poses a significant challenge. Based on our own optimized balsalazide-derived sirtuin 5 inhibitors, this work presents a systematic investigation of the inhibitory effects of derivatives with moieties that were guided by docking experiments to target the nicotinamide ribose vicinal hydroxy groups of the essential co-factor NAD+ via reversible covalent binding to potentially enhance their potency. Our results show that functionalizations with these moieties were tolerated to some extent and possessed a distinct stereo-selective preference. The (S)-configured cyanomethyl derivative 50 with an IC50 of 27 µM emerged from our synthesized library of compounds as the most potent functionalized inhibitor and lies in a similar potency range to other established sirtuin 5 inhibitors. Our findings offer a deeper insight into the structure–activity relationships of our balsalazide-derived heterotriaryl-based sirtuin 5 inhibitors and thus could provide an avenue for further optimizations in the future.
Open AccessBalsalazide-Derived Heterotriaryls as Sirtuin 5 Inhibitors: A Case Study of a Reversible Covalent Inhibition Strategy
Sirtuin 5 is an NAD+-dependent lysine deacylase that is involved in various biological processes and has emerged as a promising target for pharmaceutical therapies. The development of highly potent and subtype-selective sirtuin 5 inhibitors for their application as chemical tools and drug candidates still poses a significant challenge. Based on our own optimized balsalazide-derived sirtuin 5 inhibitors, this work presents a systematic investigation of the inhibitory effects of derivatives with moieties that were guided by docking experiments to target the nicotinamide ribose vicinal hydroxy groups of the essential co-factor NAD+ via reversible covalent binding to potentially enhance their potency. Our results show that functionalizations with these moieties were tolerated to some extent and possessed a distinct stereo-selective preference. The (S)-configured cyanomethyl derivative 50 with an IC50 of 27 µM emerged from our synthesized library of compounds as the most potent functionalized inhibitor and lies in a similar potency range to other established sirtuin 5 inhibitors. Our findings offer a deeper insight into the structure–activity relationships of our balsalazide-derived heterotriaryl-based sirtuin 5 inhibitors and thus could provide an avenue for further optimizations in the future.
- Open Access
- 19 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5419-5440
Tailored SirReal-type inhibitors enhance SIRT2 inhibition through ligand stabilization and disruption of NAD + co-factor binding
The duality of halogen-bonding-mediated ligand stabilization and the inteference of NAD + co-factor binding represents an effective strategy in the development of highly potent SIRT2 inhibitors.
- 19 August 2025
- Published by Royal Society of Chemistry (RSC) in RSC Medicinal Chemistry
- Vol. 16 (11) , 5419-5440
Open AccessTailored SirReal-type inhibitors enhance SIRT2 inhibition through ligand stabilization and disruption of NAD + co-factor binding
The duality of halogen-bonding-mediated ligand stabilization and the inteference of NAD + co-factor binding represents an effective strategy in the development of highly potent SIRT2 inhibitors.
- Open Access
- 12 May 2025
- Published by MDPI AG in Preprints.org
Lead Structure‐Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal‐Type Sirt2 Inhibitors
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic approach for the treatment of hitherto incurable diseases such as Parkinson's disease, Huntington’s disease, Alzheimer's disease and multiple sclerosis. Guided by docking studies, a lead structure-based hybridization concept was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93 we present a highly potent and selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and extends current structure-activity relationships. The structural modification strategy employed in this study proved to be a highly promising approach, resulting in the identification of the most potent low-molecular Sirt2 inhibitors reported to date.
- 12 May 2025
- Published by MDPI AG in Preprints.org
Open AccessLead Structure‐Based Hybridization Strategy Reveals Major Potency Enhancement of SirReal‐Type Sirt2 Inhibitors
Selective and potent inhibitors of the NAD+-dependent deacetylase Sirt2 represent a valuable epigenetic approach for the treatment of hitherto incurable diseases such as Parkinson's disease, Huntington’s disease, Alzheimer's disease and multiple sclerosis. Guided by docking studies, a lead structure-based hybridization concept was developed, resulting in a series of very effective Sirt2 inhibitors. With RW-93 we present a highly potent and selective Sirt2 inhibitor (IC50 = 16 nM), which as a next generation SirReal-type inhibitor significantly surpasses established Sirt2 inhibitors and extends current structure-activity relationships. The structural modification strategy employed in this study proved to be a highly promising approach, resulting in the identification of the most potent low-molecular Sirt2 inhibitors reported to date.
- 7 January 2021
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 53 (11) , 1943-1954
A Short Approach to N-Aryl-1,2,3,4-tetrahydroisoquinolines from N-(2-Bromobenzyl)anilines via a Reductive Amination/Palladium-Catalyzed Ethoxyvinylation/Reductive N-Alkylation Sequence
N-Aryl-1,2,3,4-tetrahydroisoquinolines are obtained via a convenient and short protocol with a broad range of substituents on both aromatic rings and high functional group tolerance. Starting from readily available ortho-brominated aromatic aldehydes and primary aromatic amines, condensation of these building blocks under reductive conditions gives N-aryl 2-bromobenzylamines. The C-3/C-4-unit of the tetrahydroisoquinoline is introduced using commercially available 2-ethoxyvinyl pinacolboronate under Suzuki conditions. Finally, the obtained crude ortho-ethoxyvinyl benzylamines are cyclized via an intramolecular reductive amination using the combination of triethylsilane/TFA to give the desired N-aryl-1,2,3,4-tetrahydroisoquinolines.
- 7 January 2021
- Published by Georg Thieme Verlag KG in Synthesis
- Vol. 53 (11) , 1943-1954
A Short Approach to N-Aryl-1,2,3,4-tetrahydroisoquinolines from N-(2-Bromobenzyl)anilines via a Reductive Amination/Palladium-Catalyzed Ethoxyvinylation/Reductive N-Alkylation Sequence
N-Aryl-1,2,3,4-tetrahydroisoquinolines are obtained via a convenient and short protocol with a broad range of substituents on both aromatic rings and high functional group tolerance. Starting from readily available ortho-brominated aromatic aldehydes and primary aromatic amines, condensation of these building blocks under reductive conditions gives N-aryl 2-bromobenzylamines. The C-3/C-4-unit of the tetrahydroisoquinoline is introduced using commercially available 2-ethoxyvinyl pinacolboronate under Suzuki conditions. Finally, the obtained crude ortho-ethoxyvinyl benzylamines are cyclized via an intramolecular reductive amination using the combination of triethylsilane/TFA to give the desired N-aryl-1,2,3,4-tetrahydroisoquinolines.